Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)

Overview of attention for article published in Trials, February 2022

Altmetric Badge

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 22 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 20,624 followers.

RT @FlavioRochaMD: @ZhiVenFongMD @JeyarajahRohan @AmrAliRagab @cutitoutPODCAS1 @shimulshah73 @abubakarhaf @Gio_Marchegiani @IHPBA @ALLIANCE…

26 May 2022

Reply Repost Favourite

@ZhiVenFongMD @JeyarajahRohan @AmrAliRagab @cutitoutPODCAS1 @shimulshah73 @abubakarhaf @Gio_Marchegiani @IHPBA @ALLIANCE_org @SWOG Outside of a clinical trial, unlikely. In 🇯🇵, there is a current phase III trial based on promising phase II with IV/IP pacli

25 May 2022

Reply Repost Favourite

New article: Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study) https://t.co/DwAywNusRY #pancreaticcancer #onco

07 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.